drugset / Trial / NCT00174603

Treatment of Depression With Quetiapine

NCT00174603

Phase 3 Terminated 60 enrolled Rush University Medical Center AstraZeneca · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to examine the mood stabilizing and antipsychotic properties of quetiapine in the treatment of depression by comparing subjects who were randomly assigned to either quetiapine monotherapy, quetiapine and citalopram; or haloperidol and citalopram. We hypothesize that quetiapine monotherapy would have similar effects to the combination of a first generation antipsychotic plus an antidepressant for the treatment of a major depressive episode with psychosis.

Timeline

Start
2005-08
Primary completion
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule